EMEA-003315-PIP01-22
Submitted by Anonymous (not verified) on 2 October 2024 - 17:35
EMEA-003315-PIP01-22
EMEA-003313-PIP01-22
Submitted by Anonymous (not verified) on 2 October 2024 - 17:29
EMEA-003313-PIP01-22
EMEA-003304-PIP01-22
Submitted by Anonymous (not verified) on 2 October 2024 - 17:21
EMEA-003304-PIP01-22
EMEA-003301-PIP01-22
Submitted by Anonymous (not verified) on 2 October 2024 - 16:48
EMEA-003301-PIP01-22
EMEA-003290-PIP01-22
Submitted by Anonymous (not verified) on 2 October 2024 - 16:28
EMEA-003290-PIP01-22
EMEA-003274-PIP01-22
Submitted by Anonymous (not verified) on 2 October 2024 - 16:03
EMEA-003274-PIP01-22
EMEA-003271-PIP01-22
Submitted by Anonymous (not verified) on 2 October 2024 - 15:41
EMEA-003271-PIP01-22
Orphan designation: Antisense oligonucleotide complementary to the exonic splicer enhancer sequence at intron 26 of the centrosomal protein 290 pre-mRNA Treatment of Leber's congenital amaurosis, 28/04/2016 Positive
Submitted by Anonymous (not verified) on 2 October 2024 - 15:40
Orphan designation: Antisense oligonucleotide complementary to the exonic splicer enhancer sequence at intron 26 of the centrosomal protein 290 pre-mRNA Treatment of Leber's congenital amaurosis, 28/04/2016 Positive
Orphan designation: ultevursen Treatment of retinitis pigmentosa, 22/02/2018 Positive
Submitted by Anonymous (not verified) on 2 October 2024 - 15:40
Orphan designation: ultevursen Treatment of retinitis pigmentosa, 22/02/2018 Positive
Orphan designation: erlotinib Treatment of patients with Olmsted syndrome, 09/12/2020 Positive
Submitted by Anonymous (not verified) on 2 October 2024 - 15:40
Orphan designation: erlotinib Treatment of patients with Olmsted syndrome, 09/12/2020 Positive